Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable … (Business Wire via Yahoo! Finance)

More info…
CAMBRIDGE, Mass.—-Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension for the treatment of opioid dependence.

naltrexone drug